Metrics to compare | CESSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCESSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.7x | −15.3x | −0.4x | |
PEG Ratio | −0.43 | −6.45 | 0.00 | |
Price/Book | 20.3x | 1.6x | 2.6x | |
Price / LTM Sales | 41.2x | 1.4x | 3.1x | |
Upside (Analyst Target) | - | 81.7% | 48.3% | |
Fair Value Upside | Unlock | −1.0% | 6.2% | Unlock |
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.